Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions

O. Alagoz, D. Durham, K. Kasirajan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


We evaluated the cost-effectiveness of one-time pharmacogenomic testing for preventing adverse drug reactions (ADRs) over a patient's lifetime. We developed a Markov-based Monte Carlo microsimulation model to represent the ADR events in the lifetime of each patient. The base-case considered a 40-year-old patient. We measured health outcomes in life years (LYs) and quality-adjusted LYs (QALYs) and estimated costs using 2013 US$. In the base-case, one-time genetic testing had an incremental cost-effectiveness ratio (ICER) of $43 165 (95% confidence interval (CI) is ($42 769,$43 561)) per additional LY and $53 680 per additional QALY (95% CI is ($53 182,$54 179)), hence under the base-case one-time genetic testing is cost-effective. The ICER values were most sensitive to the average probability of death due to ADR, reduction in ADR rate due to genetic testing, mean ADR rate and cost of genetic testing.

Original languageEnglish (US)
Pages (from-to)129-136
Number of pages8
JournalPharmacogenomics Journal
Issue number2
StatePublished - Apr 1 2016
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology


Dive into the research topics of 'Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions'. Together they form a unique fingerprint.

Cite this